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Midwall Fibrosis Is an Independent Predictor of
Mortality in Patients With Aortic Stenosis
Marc R. Dweck, MD,*† Sanjiv Joshi, MD,* Timothy Murigu, BSC,* Francisco Alpendurada, MD,*
Andrew Jabbour, MD,* Giovanni Melina, MD,* Winston Banya, MSC,* Ankur Gulati, MD,*‡
Isabelle Roussin, MD,* Sadaf Raza,* Nishant A. Prasad,* Rick Wage, BSC,* Cesare Quarto, MD,*
Emiliano Angeloni, MD,* Simone Refice, MD,* Mary Sheppard, MD,* Stuart A. Cook, MD, PHD,*
Philip J. Kilner, MD, PHD,*‡ Dudley J. Pennell, MD,*‡ David E. Newby, MD, DSC,†
Raad H. Mohiaddin, MD,*‡ John Pepper, MD,* Sanjay K. Prasad, MD*‡
London and Edinburgh, United Kingdom
Objectives The goal of this study was to assess the prognostic significance of midwall and infarct patterns of late gadolin-
ium enhancement (LGE) in aortic stenosis.
Background Myocardial fibrosis occurs in aortic stenosis as part of the hypertrophic response. It can be detected by LGE,
which is associated with an adverse prognosis in a range of other cardiac conditions.
Methods Between January 2003 and October 2008, consecutive patients with moderate or severe aortic stenosis undergoing
cardiovascular magnetic resonance with administration of gadolinium contrast were enrolled into a registry. Patients
were categorized into absent, midwall, or infarct patterns of LGE by blinded independent observers. Patient follow-up
was completed using patient questionnaires, source record data, and the National Strategic Tracing Service.
Results A total of 143 patients (age 68  14 years; 97 male) were followed up for 2.0  1.4 years. Seventy-two under-
went aortic valve replacement, and 27 died (24 cardiac, 3 sudden cardiac deaths). Compared with those with no
LGE (n  49), univariate analysis revealed that patients with midwall fibrosis (n  54) had an 8-fold increase in
all-cause mortality despite similar aortic stenosis severity and coronary artery disease burden. Patients with an
infarct pattern (n  40) had a 6-fold increase. Midwall fibrosis (hazard ratio: 5.35; 95% confidence interval: 1.16
to 24.56; p  0.03) and ejection fraction (hazard ratio: 0.96; 95% confidence interval: 0.94 to 0.99; p  0.01)
were independent predictors of all-cause mortality by multivariate analysis.
Conclusions Midwall fibrosis was an independent predictor of mortality in patients with moderate and severe aortic stenosis.
It has incremental prognostic value to ejection fraction and may provide a useful method of risk stratification.
(The Prognostic Significance of Fibrosis Detection in Cardiomyopathy; NCT00930735) (J Am Coll Cardiol 2011;
58:1271–9) © 2011 by the American College of Cardiology Foundation
Aortic stenosis is a progressive condition that is character-
ized by a long and indolent asymptomatic phase followed by
a shorter symptomatic stage. The onset of symptoms is
associated with an increased morbidity and a high mortality
(1). However, there is marked heterogeneity between symp-
tom onset and severity of valvular stenosis. There are several
potential explanations for this apparent mismatch, but the
hypertrophic response of the left ventricle may contribute to
the development of symptoms and adverse events.
See page 1280
Aortic stenosis results in increased pressure afterload and
ventricular wall stress, thereby stimulating left ventricular
hypertrophy (LVH). Initially, increased wall thickness
maintains normal wall stress and contraction (2,3) but
ultimately this becomes maladaptive. Indeed, LVH is an
independent predictor of cardiac mortality, regardless of
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etiology (4–6). Histopathologic
studies have demonstrated fibro-
sis in the left ventricle of patients
with aortic stenosis and arterial
hypertension (7,8). It has been
postulated that increasing myo-
cyte size eventually leads to myo-
cyte apoptosis and subsequently
replacement fibrosis, and that
this sequence is responsible for
the progression from LVH to
heart failure (9). Myocardial fi-
brosis has also been linked to the
development of arrhythmia and
sudden cardiac death in a variety
of conditions (10–13).
Cardiovascular magnetic reso-
nance (CMR) is able to detect replacement myocardial
fibrosis noninvasively by using late gadolinium enhance-
ment (LGE) (14). More recent studies have demonstrated a
midwall pattern of enhancement in patients with aortic
stenosis in the absence of coronary artery disease (15,16).
Although the use of LGE is associated with an adverse
prognosis in other cardiac conditions (17–21), this tech-
nique has not been assessed in aortic stenosis. The goal of
this study was to determine the prognostic implications of
LGE in patients with moderate and severe forms of this
disease.
Methods
Patient population. We performed a prospective, observa-
tional study of consecutive patients with aortic stenosis who
attended the Royal Brompton Hospital between January
2003 and October 2008 for CMR that included gadolinium
injection. All patients referred for CMR in this time period
with moderate or severe aortic stenosis (based on Doppler
echocardiographic demonstration of peak aortic valve pres-
sure gradient 36 mm Hg and peak transvalvular velocity
3 m/s, according to American College of Cardiology/
American Heart Association criteria [22]), were enrolled
into a registry and followed up as described in the following
text. In our institution, local guidelines recommend CMR
for all patients with severe aortic stenosis. Other reasons for
referral included diagnostic evaluation, clarification of dis-
ease severity, pre-operative evaluation, and assessment of
the hypertrophic response. Exclusion criteria were dissem-
inated malignancy; moderate or severe aortic regurgitation,
mitral regurgitation, or mitral stenosis; contraindications to
CMR, including pacemaker and defibrillator implantation;
and an estimated glomerular filtration rate (Cockcroft-
Gault equation) of 30 ml/min. The study was conducted
after local research ethics committee approval in 2003 and in
accordance with the Declaration of Helsinki.
Data collection. Demographic characteristics and medical
history were documented from source patient record data
and patient questionnaires. The presence of coronary artery
disease was defined as a prior coronary revascularization or
the presence of significant coronary artery stenosis as as-
sessed by single-photon emission computed tomography,
invasive coronary angiography (50% lumen diameter nar-
rowing), or computed tomography coronary angiography.
Cardiovascular magnetic resonance. CMR was per-
formed using a 1.5-T scanner (Magnetom Sonata or
Avanto, Siemens, Erlangen, Germany) and a standardized
protocol with stable study parameters. Steady-state free
precession sequences were used for aortic valve planimetry
and for the assessment of left ventricular (LV) volumes and
mass. Ten to fifteen minutes after injection of 0.1 mmol/kg
of gadolinium contrast agent (Gd-DTPA, Schering AG,
Berlin, Germany), inversion recovery–prepared spoiled gra-
dient echo images were acquired in standard long- and
short-axis views to detect areas of LGE as described
previously (18). Inversion times were optimized to null
normal myocardium with images repeated in 2 separate
phase-encoding directions to exclude artifact.
Image analysis. The severity of aortic stenosis was assessed
using CMR-derived planimetry of the aortic valve area.
This technique has been validated against echocardio-
graphic measures of aortic stenosis severity (23). In accor-
dance with American College of Cardiology/American
Heart Association guidelines, aortic stenosis was graded
using the aortic valve area as follows: mild, 1.5 cm2;
moderate, 1.5 to 1.0 cm2; and severe, 1.0 cm (22). For
quantification of LV function and volumes, the endocardial
and epicardial contours were semi-automatically applied in
end-systole and -diastole using dedicated software (CMR-
tools, Cardiovascular Imaging Solutions Ltd., London,
United Kingdom). LV mass was calculated from the total
end-diastolic myocardial volume multiplied by the specific
gravity of the myocardium (1.05 g/ml). LV mass and
volumes were indexed to body surface area, age, and sex, and
were considered abnormal if they were outside the 95th
percentile (24).
The presence and pattern of LGE were assessed by 2
independent observers who were blinded to the clinical data,
including valve severity, coronary anatomy, and outcomes.
A third blinded observer adjudicated when there was a
disparity between the initial 2 observers. Patients with a
mixed pattern of LGE were categorized according to the
predominant pattern of fibrosis.
LGE mass was calculated semi-automatically by a single
operator using MRI-MASS software (Medis, Leiden, the
Netherlands). The endocardial and epicardial borders were
traced for each short-axis slice. A region of interest averag-
ing 50 mm2 was defined within normal remote myocardium
in an area with uniform myocardial suppression free of
artifacts. A multi-pass region-growing algorithm was used
to identify the fibrotic boundaries based on the “full width
half maximum” technique, and fibrosis was expressed as
present or absent, and its extent was quantified as a
percentage of total LV mass (% LGE mass).
Abbreviations
and Acronyms
AVR  aortic valve
replacement
CI  confidence interval
CMR  cardiovascular
magnetic resonance
HR  hazard ratio
LGE  late gadolinium
enhancement
LV  left ventricular
LVEDV  left ventricular
end-diastolic volume
LVH  left ventricular
hypertrophy
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Clinical endpoints. The primary endpoint of the study was
all-cause mortality. The secondary endpoint was cardiac
mortality. Mortality data were obtained from hospital notes
and the National Strategic Tracing Service, a national
database for all National Health Service patients in the
United Kingdom. Cause of death was established from
medical notes and/or death certification records and an
assessment made as to whether this represented a sudden
cardiac death. Data regarding which patients had undergone
aortic valve replacement (AVR) during the follow-up period
were also collected.
Statistical analysis. Continuous variables were expressed
as mean  SD and compared using one-way analysis of
variance or the unpaired Student t test where appropriate.
Categorical variables were expressed as percentages and
analyzed using the chi-square test. All continuous variables
were tested for normal distribution using the Shapiro-Wilk
test. Variables with a skewed distribution were log trans-
formed and the geometric mean with the 95% confidence
intervals (CIs) reported. In situations in which log transfor-
mation did not normalize the data, analysis was performed
using nonparametric tests (Mann-Whitney rank sum test or
the Kruskal-Wallis tests, as appropriate).
Kaplan-Meier curves were used to estimate the survival
distributions with regard to all-cause mortality and cardiac
mortality for patients with no LGE, midwall LGE, and
infarct LGE. Differences in the survival patterns of the
patients in the 3 groups were assessed using the log-rank
test. Univariate and multivariate survival analyses (Cox
proportional hazards regression) were performed to deter-
mine independent predictors of all-cause mortality and
cardiac mortality. A 2-sided p value 0.05 was regarded as
statistically significant. All analyses were performed using
Stata version 10.0 (Stata Corporation, College Station,
Texas).
Results
CMR was performed on 143 consecutive patients (age 68
14 years; 97 male) with a mean aortic valve area of 0.99 
0.31 cm2. Overall, 57 patients (40%) had moderate and 86
(60%) severe aortic stenosis. CMR estimation of aortic valve
severity correlated closely with echocardiographic data. Cor-
onary artery disease was assessed in all patients (83% had
invasive coronary angiography) and was present in 81
patients (57%) (Table 1).
Baseline Characteristics of 143 Patients With Aortic Stenosis According to the Pattern of Late LGETable 1 Baseline Characteristics of 143 Patients With Aortic Stenosis According to the Pattern of Late LGE
Characteristic No LGE (n  49) Midwall LGE (n  54) Infarct LGE (n  40) p Value
Age (yrs) 64 16 70 11 70 13 0.031
Male 53 72 80 0.018
Clinical history
AF 21 18 18 0.915
Diabetes mellitus 25 19 32 0.378
Hypertension 56 55 50 0.838
Bicuspid aortic valve 29 17 23 0.401
Documented CAD 37 42 98 0.001
1-vessel 16 17 15 0.001
2-vessel 2 6 20
3-vessel 2 13 28
Previous PCI 10 9 30 0.010
Previous CABG 20 8 28 0.040
Medication
ACE inhibitor 56 48 61 0.480
Beta-blocker 56 26 49 0.007
Statins 67 60 82 0.079
Diuretic use 15 36 41 0.014
Aortic valve area by CMR (cm2) 1.05 0.37 1.00 0.31 0.91 0.26 0.111
Peak aortic valve gradient by echo (mm Hg) 70 26 70 26 69 16 0.99
Severe aortic stenosis 53 50 65 0.353
Ejection fraction (%) 69 13 58 21 44 18 0.001
Indexed LA volume (ml/m2) 58.9 (53.4–64.9) 62.9 (56.2–70.3) 63.3 (57.1–70.2) 0.560
Indexed LVEDV (ml/m2) 78.8 (72.1–86.2) 88.5 (79.4–98.6) 101.4 (92.6–111.0) 0.003
Indexed LV mass (g/m2) 92.6 (86.0–99.6) 113.7 (104.5–123.8) 97.8 (90.9–105.2) 0.005
RVEF (%) 58 13 57 12 55 14 0.450
% LGE mass 0 5.2 7.3 —
Values are mean  SD, %, or geometric mean (95% confidence interval).
AF  atrial fibrillation; ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft; CAD  coronary artery disease; CMR  cardiac magnetic resonance; LA  left atrial; LGE  late
gadolinium enhancement; % LGE mass  percentage of total left ventricular mass; LV  left ventricular; LVEDV  left ventricular end-diastolic volume; PCI  percutaneous coronary intervention; RVEF 
right ventricular ejection fraction.
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Patterns of LGE. Three patterns of LGE were observed:
no gadolinium enhancement (no LGE group); localized
enhancement consistent with prior myocardial infarction
(infarct LGE group); and a midwall pattern of enhancement
(midwall LGE group) (Fig. 1). Interobserver agreement in
determining the pattern of LGE was very good, with a
kappa value of 0.89.
LGE was absent in 49 patients (34%). There was a typical
pattern of prior myocardial infarction in 40 patients (28%)
and midwall fibrosis in 54 patients (38%) (Table 1). In 8
patients (6%), there was a dual pattern of both myocardial
infarction and midwall fibrosis. These patients were cate-
gorized according to their predominant pattern, and the
statistical analysis was performed on this basis. Seven were
placed in the infarct group and 1 in the midwall group. One
patient with midwall LGE who died underwent autopsy.
Assessment of the macroscopic appearance of the cut
surface of the heart showed myocardial fibrosis, which was
confirmed histologically using Trichome stain (Fig. 2).
Patients with no LGE were younger, more likely to be
female, and less likely to be undergoing diuretic therapy.
The severity of aortic stenosis and prevalence of cardiovas-
cular risk factors were similar to the other groups. As
anticipated, patients with an infarct pattern of LGE had
more severe coronary artery disease, lower ejection fractions,
and higher indexed LV volumes than the other groups.
Patients with midwall LGE had the highest indexed LV
mass (p 0.005) despite the fact that aortic stenosis severity
and hypertension prevalence were similar among all 3
groups. Interestingly, ejection fraction was lower (p 
0.007) in patients with midwall LGE compared with those
with no LGE, even though both groups had a similar degree
of coronary artery disease. Although there was an apparent
trend to a correlation between ejection fraction and the
midwall LGE burden (Pearson’s R –0.26; p 0.08), this
finding did not reach statistical significance. Indexed left
atrial volumes were used as a marker of diastolic dysfunction
(25), and there was no significant difference in this variable
among the 3 groups (Table 1).
Figure 1 Patterns of LGE in Aortic Stenosis
Images showing the different patterns of late gadolinium enhancement (LGE) observed in patients with aortic stenosis. (A) No LGE. (B) Infarct LGE with a subendocar-
dial pattern observed in the septum and anterior wall. (C) Two focal areas of midwall LGE in the lateral wall of the left ventricle (red arrows); (D) Midwall LGE in a more
linear pattern affecting the septum. (E) Short- and (F) long-axis views of midwall LGE (red arrows) of the inferolateral wall in the same patient.
Figure 2 Histology of the Myocardium, After Trichome Staining,
in a Patient With Midwall LGE
Black arrows demonstrate increased replacement fibrosis in the
midwall region of the myocardium.
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Mortality data. Patients were followed up for a mean of
2.0  1.4 years (median: 1.7 years). None of the patients
were lost to follow-up and, overall, 27 patients (19%) died
(Table 2). Univariate analysis revealed that compared with
patients with no LGE, there was an 8-fold increase in
all-cause mortality in patients with midwall fibrosis (HR:
8.59; 95% CI: 1.97 to 37.38; p  0.004) and a 6-fold
increase in mortality in those with myocardial infarction
(HR: 6.46; 95% CI: 1.39 to 30.00; p 0.017) (Table 3, Fig. 3).
As fibrosis burden increased, prognosis worsened: with
every 1% increase in the % LGE mass, the risk of mortality
appeared to increase by 5% (HR: 1.05; 95% CI: 1.01 to
1.09; p 0.005). A lower ejection fraction and an increased
left ventricular end-diastolic volume (LVEDV) also pre-
dicted an increased all-cause mortality on univariate
analysis.
After multivariate analysis, ejection fraction (HR: 0.96;
95% CI: 0.94 to 0.99; p  0.009) and the midwall pattern
of LGE (HR: 5.35; 95% CI: 1.16 to 24.56; p  0.0034)
were identified as independent predictors of subsequent
all-cause mortality (Table 4).
Twenty-three of the 27 deaths were from cardiac causes
(Table 2). There was a 5-fold increase in cardiac mortality in
the infarct group (HR: 5.44; 95% CI: 1.15 to 25.68; p 
0.032) and a 6-fold increase in the midwall group (HR:
6.68; 95% CI: 1.51 to 29.64; p  0.012) (Fig. 4).
Three of the deaths were adjudicated as sudden cardiac
deaths, and all were in the midwall group. Each of these
subjects had died suddenly at home with no prior symptoms
or signs of heart failure.
Aortic valve replacement. During follow-up, 72 patients
(50%) underwent AVR (8 patients percutaneously) with no
difference in rates among the 3 groups (Table 2). The
occurrence of AVR was associated with an improved sur-
vival in the univariate analysis (p  0.01) and multivariate
analyses (HR: 0.32; 95% CI: 0.13 to 0.76; p  0.01)
Outcome Data: Subsequent Aortic Valve Replacement, All-Cause Mortality,Cardiac Mor lity, and Sudden Cardi c Deaths According to the Pattern of LGETable 2 Outcome Data: Subsequent Aortic Valve Replacem nt, All-Cause Mortality,Cardiac Mortality, and Sudden Cardiac Deaths According to the Pattern of LGE
Variable No LGE Midwall LGE Infarct LGE p Value
Subsequent AVR, % 55 46 53 0.66
Deaths 2 16 9 0.003
Cardiac deaths 2 13 8 0.016
Sudden cardiac deaths 0 3 0 —
All-cause mortality rate* 15.7 142.7 173.1 —
Cardiac mortality rate* 15.7 130.2 123.2 —
All-cause mortality rate* in patients with AVR 13.7 53.8 73.6 —
All-cause mortality rate* in non-AVR patients 18.2 218.8 190.0 —
Values are the number of adverse events and themortality rates (deaths per 1,000 patient/yrs) in each group. *All-causemortality rates are also displayed
for patients who subsequently had an AVR during the period of follow-up and for those who did not (patients turned down for surgery have been excluded
from this analysis [n  2 in the midwall group, n 4 in the infarct group]). p values for mortality rates are given in Table 3 and Figures 3 and 4.
AVR  aortic valve replacement; LGE  late gadolinium enhancement.
Cox Proportional Hazards Model: Univariate Analysis for All-Cause MortalityTable 3 Cox Proportional Hazards Model: Univariate Analysis for All-Cause Mortality
Variable Dead (n  27) Alive (n  116) Hazard Ratio Confidence Interval p Value
Age (yrs) 71.5 7.8 67.1 14.3 1.03 0.99–1.07 0.12
Male 69.8 59.3 0.68 0.32–1.47 0.33
Subsequent AVR 25.9 55.2 0.32 0.13–0.75 0.01
Diabetes mellitus 23.1 24.8 0.94 0.38–2.35 0.90
Hypertension 53.9 54.0 1.02 0.47–2.21 0.95
Documented CAD 65.4 53.5 1.62 0.72–3.62 0.25
ACE inhibitors 53.9 54.6 0.95 0.44–2.05 0.89
Beta-blockers 42.3 43.2 1.00 0.45–2.18 1.00
Ejection fraction (%) 45.0 21.6 60.6 18.4 0.96 0.94–0.98 0.001
AV area (cm2) 0.96 0.31 0.99 0.31 0.68 0.19–2.40 0.55
Indexed mass (g/m2)* 116.6 34.5 103.1 28.3 1.01 1.00–1.02 0.06
Indexed LVEDV (g/ml)* 99.2 (83.7–117.7) 86.0 (81.0–91.3) 3.06 1.03–9.08 0.04
LGE pattern
No LGE 7.4 40.5 1.00 — —
Infarct LGE 33.3 26.7 6.46 1.39–30.00 0.017
Midwall LGE 59.3 32.8 8.59 1.97–37.38 0.004
% LGE mass 12.6 10.3 6.7 9.1 1.05 1.01–1.09 0.005
Values are mean SD or %. The following were found to be significant predictors of all-cause mortality: subsequent AVR, ejection fraction, indexed
LVEDV, an infarct pattern of LGE, midwall LGE, and the % LGEmass. *Natural logarithm used for analysis with proportions in the dead/alive columns
presented as actual value (natural logarithm of confidence intervals).
AVR  aortic valve replacement; % LGE mass  percentage of total left ventricular mass; other abbreviations as in Table 1.
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(Tables 3 and 4). In patients with midwall fibrosis, those
undergoing AVR had a mortality rate of 54 per 1000
patient-years compared with 219 per 1,000 patient-years in
those who did not (Table 2). The 2 groups were well
matched, with no significant differences in age (p  0.64),
aortic valve area (p  0.32), ejection fraction (p  0.24),
indexed LVEDV (p  0.29), indexed LV mass (p  0.60),
documented coronary artery disease (p  0.77), hyperten-
sion rates (p  0.10), or diabetes mellitus (p  0.23). Two
patients were turned down for surgery in the midwall group,
and they were excluded from this analysis.
Discussion
Aortic stenosis is the most common indication for valve
replacement in Europe and North America (26). Its clinical
importance continues to rise with a progressively ageing
population and the expansion of percutaneous valve implan-
tation. Here, we have investigated whether myocardial
fibrosis, as assessed by using CMR, can predict prognosis in
this condition. For the first time, we demonstrated that
midwall fibrosis/LGE is an independent predictor of sur-
vival in aortic stenosis and seems to be of incremental
prognostic value to ejection fraction.
LGE has been associated with adverse clinical outcomes
across a range of different cardiac conditions, including
hypertrophic cardiomyopathy, dilated cardiomyopathy, and
myocardial infarction (17–20). We extend here those find-
ings to patients with aortic stenosis. Patients with no LGE
had a relatively good prognosis in contrast to those with a
midwall or infarct pattern of enhancement who experienced
an 8- and 6-fold increase in mortality, respectively.
The poor prognosis associated with prior myocardial
infarction is well established in this and other settings
(17,20) and is thought to be related to arrhythmogenicity
and adverse remodeling with progression to heart failure.
The findings in relation to midwall fibrosis are less expected.
Although patients with prior infarction had a lower ejection
fraction and more severe coronary artery disease, patients
with midwall fibrosis had higher mortality. With increasing
burden of midwall LGE, prognosis worsened, and in the
multivariate survival analysis, midwall fibrosis emerged as an
independent marker of all-cause mortality. Myocardial in-
farction was not independently associated, probably because
of its close association with ejection fraction.
Midwall fibrosis in aortic stenosis. Fibrosis is a common
pathologic alteration in patients with aortic stenosis and
concurrent LVH (7). In the hypertrophied myocardium,
areas of fibrosis co-localize with areas of myocyte apoptosis
(27), and a pathological sequence of myocyte hypertrophy
followed by apoptosis and replacement fibrosis has been
described (9). Several possible triggers to this apoptotic
process have been postulated, including direct mechanical
forces (28,29) and angiotensin II (29,30). Ischemia has also
been suggested. Increased myocardial mass and afterload
lead to increased myocardial oxygen demand. The capillary
bed does not expand sufficiently to increase oxygen supply,
and capillary flow reserve is reduced (31,32), thereby induc-
ing ischemia. Galiuto et al. (33) demonstrated that patients
Cox Regression Multivariate Analysis forAll-Cause MortalityTable 4 Cox Regression Multivariate Analysis forAll-Cause Mortality
Variable Hazard Ratio 95% Confidence Interval p Value
Ejection fraction 0.96 0.94–0.99 0.01
Indexed LVEDV 0.68 0.18–2.61 0.57
Midwall LGE 5.35 1.16–24.56 0.03
Infarct LGE 2.56 0.48–13.64 0.27
Subsequent AVR 0.32 0.13–0.76 0.01
Ejection fraction, midwall LGE, and subsequent AVR all emerged as independent predictors of
all-cause mortality.
Abbreviations as in Table 3.
Figure 3
Kaplan-Meier Survival Estimates by Pattern
of LGE for All-Cause Mortality in 143 Patients
With Moderate or Severe Aortic Stenosis
There was a significant increase in all-cause mortality in the midwall (orange
dashed line) and infarct groups (green solid line) compared with the no late
gadolinium enhancement (LGE) group (blue dotted line). Among patients fol-
lowed up for more than 4 years, there were no further deaths.
Figure 4
Kaplan-Meier Survival Estimates by Pattern
of LGE for Cardiac Mortality in 143 Patients
With Moderate or Severe Aortic Stenosis
There was a significant increase in cardiac mortality in the midwall (orange
dashed line) and infarct groups (green solid line) compared with the no late
gadolinium enhancement (LGE) group (blue dotted line). Among patients fol-
lowed up for more than 4 years, there were no further deaths.
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with severe aortic stenosis and no coronary artery disease
have impaired myocardial perfusion and increased cardio-
myocyte apoptosis. However, the concept that midwall
fibrosis is due to hypoperfusion remains unproven, and one
might expect ischemia due to hypertrophy to be greatest in
the subendocardium, not the midwall.
Midwall LGE is associated with an increased LV mass
(15,16), being on average 11 g/m2 higher in our study than
in those patients without fibrosis. The explanation for this
increase is not clear, given that there were no differences in
the severity of aortic valve disease or rates of hypertension
between the groups. Other factors are likely to be involved,
including age, male sex (34–36), use of beta-blockers
(37,38), and different genotypes (34,39,40).
It is unlikely that midwall fibrosis occurs secondary to
coronary artery disease. Previous studies have reported that
midwall LGE occurs in patients with aortic stenosis and
normal coronary arteries (15,16). In our study, the presence
of coronary artery disease was well characterized, with no
difference in its presence between the midwall and the
no-LGE groups. Furthermore, more than one-half of those
with midwall LGE had unobstructed coronary arteries.
Mechanism of adverse prognosis. The adverse prognosis
associated with midwall fibrosis in aortic stenosis seems to
be predominantly cardiac in etiology. Midwall LGE pre-
dicted a 6-fold increase in cardiac mortality compared with
no LGE, and 81% of deaths in this group were cardiac in
nature.
Using CMR, we have confirmed that the ejection fraction
serves as a powerful prognostic marker in aortic stenosis (41)
and shown that it was impaired in the midwall group
compared with the no-LGE group. Impaired LV function
is therefore likely to be a major contributor to the adverse
prognosis in these patients. However, on multivariate anal-
ysis, midwall fibrosis still predicted an increased mortality
after adjustment for the effects of ejection fraction, which
suggests the contribution of other factors.
One potential mechanism may be arrhythmogenicity.
Fibrosis can serve as a structural substrate for arrhythmia
(42), and its detection, using LGE, in patients with dilated
cardiomyopathy or previous myocardial infarction has been
linked to an increased incidence of arrhythmia and sudden
cardiac death (18,43). In this study, all 3 patients with aortic
stenosis who had a sudden cardiac death were in the
midwall group. However, our study design was not ade-
quately powered to examine this endpoint, and our protocol
did not include routine ambulatory monitoring. In addition,
other patients may have died suddenly without there being
sufficient documentation to allow their identification within
this study. It is therefore not possible to make any definitive
assertions about the contribution of malignant arrhythmia
to the adverse prognosis associated with midwall LGE in
aortic stenosis. Although further work is required to evalu-
ate this question, in our opinion the effect of midwall
fibrosis on LV function is likely to represent the predomi-
nant mechanism.
Aortic valve replacement. Nearly one-half of our cohort
underwent AVR during follow-up. The high rates of
surgery probably underlie our observation that aortic steno-
sis severity was not predictive of mortality. AVR is the only
available treatment capable of improving the prognosis of
patients with symptomatic severe aortic stenosis and, in our
study, was predictive of an improved outcome after multi-
variate analysis.
It is noteworthy that AVR appeared to modulate the poor
prognosis associated with midwall fibrosis. After excluding
patients turned down for surgery, patients with midwall
LGE who had an AVR were 4 times less likely to die over
the course of the follow-up than those who did not undergo
AVR (Table 2). This is despite the 2 groups being well
matched in terms of age, indexed LVEDV, ejection frac-
tion, aortic valve area, indexed LV mass, hypertension,
diabetes mellitus, and concomitant coronary artery disease.
Furthermore, more than one-half of the patients with
midwall fibrosis who died had moderate aortic stenosis and
would not have been considered for AVR under conven-
tional management practice. Myocardial fibrosis may there-
fore have a role in the risk stratification of patients being
considered for surgery.
Interestingly, it would appear that once established,
midwall fibrosis is not reversible after AVR. Weidemann et
al. (44) found no change in the degree of LGE 9 months
after AVR. In our study, CMR was repeated in 1 patient a
year after surgery. The presence of midwall fibrosis and the
% LGE mass remained unchanged (4.6% at baseline vs.
4.4% after 1 year).
In accordance, the adverse prognosis associated with
midwall fibrosis also persists to a degree after AVR. The
mortality rate among patients in the midwall group who
underwent AVR was 53.8 per 1,000 patient-years compared
with 13.7 per 1,000 patient-years in the no-LGE group.
The benefit of AVR in midwall fibrosis may instead be
related to the prevention of subsequent fibrosis and the
further associated increases in LV dysfunction and tendency
to arrhythmia.
Study limitations. Twenty-seven patients died during the
course of our study, so that fitting more than 3 variables into
the multivariate analysis may be problematic. Post-hoc
analysis performed using the homoscedastic adjustment
inflation factor suggest that there was no evidence of
overfitting in our model. Nevertheless, a multicenter study
involving a larger cohort with longer follow-up is required
for confirmation of our findings and definitive conclusions
about differential risk based on multivariate analysis. Further
attention must also be paid to the mechanisms underlying
the increased mortality (including the incidence of arrhyth-
mia, sudden cardiac death, and symptoms) and the role of
AVR in modulating this risk. Ultimately, such studies may
pave the way for randomized controlled trials of antifibrotic
medications in the treatment of this common clinical
condition.
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In our institution, local guidelines recommend CMR for
all patients with severe aortic stenosis. However, because
patients with moderate disease were referred at the discre-
tion of their clinician, there may have been some referral
bias in this group.
Finally, established LGE techniques detect areas of
replacement fibrosis within the myocardium. Diffuse inter-
stitial fibrosis can be detected using T1 mapping techniques
(45), and this has not been assessed in our study. Although
this form of fibrosis predominates in aortic stenosis, T1
mapping has not been validated, whereas LGE is already
established in everyday clinical practice.
Conclusions
We have shown that CMR-detected midwall fibrosis is an
independent predictor of mortality in patients with moder-
ate and severe aortic stenosis and is of incremental value in
the prognostic model to ejection fraction. It may prove to be
a useful method of risk stratification in patients with
advanced aortic valve disease or as a future target for
antifibrotic medication.
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